---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-119760"
form_type: "8-K"
ticker: "HYPD"
cik: "0001682639"
company_name: "HYPERION DEFI, INC."
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-29T23:49:32.826733+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Eyenovia Phase 3 CHAPERONE myopia trial fails; cuts 50% staff, explores strategic options

## Summary
- Independent DRC found CHAPERONE not meeting primary endpoint of <0.5 diopter progression over 3 years; study terminated.
- 252 evaluable patients; no significant difference between active arms (0.01% and 0.1% atropine) and placebo.
- Workforce reduction of ~50% with $0.2M severance; remaining staff focused on Optejet Gen-2, dry eye collaborations, clobetasol.
- Company evaluating strategic options: business combination, reverse merger, or asset sales.
- Safety profile acceptable; mild and infrequent adverse events across all doses.

## SEC filing metadata
- accession: 0001104659-24-119760
- form_type: 8-K
- ticker: HYPD
- cik: 0001682639
- company_name: HYPERION DEFI, INC.
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682639/000110465924119760/0001104659-24-119760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682639/000110465924119760/tm2428238d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-119760
- JSON: https://secwatch.observer/filing/0001104659-24-119760.json
- Plain text: https://secwatch.observer/filing/0001104659-24-119760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.